PUBLISHER: DelveInsight | PRODUCT CODE: 2064040
PUBLISHER: DelveInsight | PRODUCT CODE: 2064040
Lanifibranor became one of the first MASH candidates to demonstrate statistically significant improvement in both key FDA-relevant histologic endpoints in a Phase IIb trial.
In the NATIVE Phase IIb study:
The results were subsequently published in the New England Journal of Medicine, significantly increasing scientific credibility and investor confidence.
MASH/NASH represents one of the largest unmet needs in hepatology, with millions of patients globally progressing toward cirrhosis, liver failure, and transplantation.
Lanifibranor is being positioned for patients with:
The approval of Rezdiffra validated the commercial potential of the MASH market and increased attention on next-generation oral therapies with stronger fibrosis benefits.
Inventiva announced in April 2025 that the pivotal Phase III NATiV3 trial completed enrollment with:
Topline Phase III results are expected in the second half of 2026, and positive data could support:
Completion of enrollment substantially reduces operational uncertainty and improves investor visibility into the regulatory timeline.
Unlike therapies targeting a single metabolic pathway, lanifibranor activates:
This broad mechanism may provide:
In diabetic MASH patients, lanifibranor demonstrated improvements in glycemic parameters in addition to liver histology, which may become commercially important because a large proportion of MASH patients also have obesity and type 2 diabetes.
Multiple independent Data Monitoring Committee (DMC) reviews recommended continuation of the Phase III NATiV3 study without protocol modification.
The fifth DMC review in 2024 evaluated safety data from more than:
Inventiva stated that these reviews continue confirming the "good safety profile" of lanifibranor, an important factor in chronic metabolic disease therapy adoption.
IVA-337 Recent Developments
Inventiva, an emerging biopharmaceutical company developing innovative therapies notably to treat especially fibrosis, announced the beginning of patient enrollment for its Phase IIb clinical trial (NATIVE - NASH Trial to Validate IVA337 Efficacy) evaluating the Company's lead compound, IVA337, for the treatment of Non-Alcoholic Steatohepatitis (NASH).
"IVA-337 Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of IVA-337 for potential indication like Fibrosis, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease, and Type 2 diabetes mellitus in the 7MM. A detailed picture of IVA-337's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IVA-337 for potential indications. The IVA-337 market report provides insights about IVA-337's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IVA-337 performance, future market assessments inclusive of the IVA-337 market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IVA-337 sales forecasts, along with factors driving its market.
IVA-337 Drug Summary
IVA-337 is an investigational oral pan-peroxisome proliferator-activated receptor (PPAR) agonist developed by Inventiva Pharma for the treatment of metabolic and fibrotic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The drug activates all three PPAR isoforms-PPAR-a, PPAR-δ, and PPAR-Y-helping regulate lipid metabolism, glucose homeostasis, inflammation, and fibrosis, thereby addressing multiple underlying mechanisms involved in progressive liver disease. Administered orally once daily, IVA-337 has demonstrated promising efficacy in reducing liver inflammation and fibrosis progression while improving metabolic parameters in patients with MASH/NASH. In the Phase IIb NATIVE trial, lanifibranor achieved significant improvements in steatohepatitis resolution and fibrosis markers compared with placebo, supporting its advancement into the pivotal Phase III NATiV3 study. The therapy has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration for MASH/NASH with fibrosis, and ongoing studies continue to evaluate its long-term efficacy, cardiovascular benefits, and safety profile, which has generally included gastrointestinal adverse events, weight gain, and peripheral edema. The report provides IVA-337's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the IVA-337 Market Report
The report provides insights into:
The IVA-337 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
IVA-337 Analytical Perspective by DelveInsight
This IVA-337 sales market forecast report provides a detailed market assessment of IVA-337 for potential indication like Fibrosis, Non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease, and Type 2 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IVA-337 sales data uptil 2034.
The IVA-337 market report provides the clinical trials information of IVA-337 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
IVA-337 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
IVA-337 Market Potential & Revenue Forecast
IVA-337 Competitive Intelligence
IVA-337 Regulatory & Commercial Milestones
IVA-337 Clinical Differentiation
IVA-337 Market Report Highlights